SCHEMBL2824923

SCHEMBL2824923

CCOC(=O)c1cnn(Cc2ccc(F)c(F)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.57
KLKB1 P03952 3/20 0.53
ALDH1A1 P00352 3/20 0.47
POLB P06746 2/20 0.45
S1PR3 Q99500 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 2/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
ADORA1 P30542 1/20 0.42
HSD17B10 Q99714 2/20 0.41
KMT2A Q03164 1/20 0.41
SCD O00767 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALOX15 P16050 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30755417 1.00 GRM2 (0.57) GRM2KLKB1ALDH1A1POLBS1PR3
SCHEMBL25911626 0.90 GRM2 (0.55) GRM2KLKB1ALDH1A1POLBSMN1; SMN2
SCHEMBL27379021 0.88 GRM2 (0.52) GRM2KLKB1ALDH1A1POLBSMN1; SMN2
SCHEMBL3093449 0.86 GRM2 (0.63) GRM2KLKB1ALDH1A1POLBSMN1; SMN2
SCHEMBL3092869 0.85 HSD17B10 (0.51) GRM2KLKB1ALDH1A1POLBSMN1; SMN2
SCHEMBL1909166 0.84 GRM2 (0.53) GRM2KLKB1ALDH1A1HSD17B10KMT2A
SCHEMBL4767882 0.84 GRM2 (0.56) GRM2KLKB1POLBSMN1; SMN2HPGD
SCHEMBL27379736 0.84 GRM2 (0.55) GRM2KLKB1ALDH1A1S1PR3SMN1; SMN2
SCHEMBL2821953 0.83 LMNA (0.54) GRM2KLKB1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL28595790 0.83 ESR1 (0.55) GRM2KLKB1ALDH1A1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS INC (US) 2026-02-05 US disclosed
WO-2024026483-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
US-20100184815-A1 AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK1, CDK20 GRM2 1339/4885KLKB1 4846/4885ALDH1A1 4103/4885
US-20100184815-A1 AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA PPARA, PPARD, PPARG GRM2 849/4885KLKB1 1854/4885ALDH1A1 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.